The document outlines a solicitation for pharmaceutical supplies by the Department of Veterans Affairs (VA) under the National Acquisition Center. The RFP delineates the requirements for supply contracts specifically for Hydroxychloroquine SO4 200mg tablets in two configurations, detailing quantities and pricing for the base year and four options. Submission criteria include providing a unique National Drug Code (NDC) for each product, compliance with manufacturing standards, and appropriate regulatory documentation. The solicitation specifies the length of the contract, implementation periods, and the structure for pricing, which includes a 0.5% Cost Recovery Fee. Contractors are required to have acceptable Good Manufacturing Practices (cGMP) status with the FDA, and also adhere to the Drug Supply Chain Security Act (DSCSA) for serialization and tracking. Performance will be evaluated based on timely delivery and compliance with contract terms. This procurement aims to secure a consistent supply of pharmaceuticals for various government healthcare facilities, ensuring both availability and pricing stability within compliance frameworks. The document emphasizes adherence to regulations and the integration of efficient supply chain practices for government entities.

The Department of Veterans Affairs (VA) is issuing a Request for Proposal (RFP) 36E79725R0022 for an unrestricted procurement of Hydroxychloroquine SO4 Tablets. This procurement serves various federal entities, including the Department of Defense, Bureau of Prisons, and Indian Health Service. The contract period spans one year with four optional one-year extensions, aimed at ensuring a continuous supply of the drug. Offerors must provide their unique National Drug Code (NDC) without labeling over existing labels. The solicitation will be available electronically on or around March 12, 2025, with submissions due by March 26, 2025. The estimated annual requirements total 163,395 bottles of 100-count and 25,853 bottles of 500-count Hydroxychloroquine tablets. Interested parties must monitor SAM.gov for updates and communicate with the contracting officer, Chris Carthron, for inquiries. This RFP reflects the VA's ongoing efforts to secure essential medications for veteran and federal healthcare programs.

The document is an amendment to solicitation number 36E79725R0022 issued by the Department of Veterans Affairs, specifically the National Acquisition Center. The primary purpose of this amendment is to extend the deadline for offers concerning Hydroxychloroquine SO4 200MG Tabs. The new due date is set for April 8, 2025, at 2:30 PM CDT, an extension from the previous deadline of April 1, 2025. All other terms and conditions of the original solicitation remain unchanged. The document is formally signed by Christopher Carthron, the contracting officer, who oversees the amendment process. This amendment underscores the importance of timely communication to bidders and sets clear expectations regarding offer submissions in a federal procurement context.